摘要:
The invention is related to the field of immunotherapy, and concerns novel ligands for the CD4 molecule, mutant Fab 13B8.2 fragments of the CD4 antibody binding the CD4 molecule and comprising a mutation of at least one residue in a position located in the variable domain VH of the heavy chain and/or in a position located in the variable domain Vλ of the light chain. The invention also concerns pharmaceutical compositions containing said ligands for treating pathologies wherein the CD4 molecule is involved.